This page shows the latest Forteo news and features for those working in and with pharma, biotech and healthcare.
Tymlos is a parathyroid hormone-related protein (PTHrP) analogue that competes most closely with Eli Lilly's ageing osteoporosis drug Forteo (teriparatide) and could become a $1bn-plus product at peak, ... Forteo is heading for patent expiry, so Radius'
CHMP recommends Merck &Co's Lantus biosimilar. Also backs two biosimilar versions of Lilly’ s osteoporosis therapy Forteo. ... Forteo biosimilars. Meanwhile, the CHMP this month also issued positive opinions for two versions of Lilly's big-selling
Their anti-sclerostin antibody romosozumab is well ahead of other drugs in the emerging class and has been shown to be superior to Eli Lilly's big-selling osteoporosis therapy Forteo
Forteo is widely used in osteoporosis therapy and brought in sales of around $1.35bn last year. ... Amgen and UCB previously reported data showing romosozumab was superior to Forteo, which also requires daily dosing by injection.
Amgen and UCB have previously reported data showing romosozumab was superior to Eli Lilly's parathyroid hormone-based Forteo (teriparatide), which requires daily dosing by injection. ... Forteo is widely used in osteoporosis therapy and brought in sales
Forteo (teriparatide).
More from news
Approximately 1 fully matching, plus 19 partially matching documents found.
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...